A retrospective study of the relationship between high-dose methotrexate chemotherapy-related toxicity and concomitant drugs: Non-steroidal anti-inflammatory drugs and sulfametoxazole

Yoshihiko Shibayama, Takuya Sata, Yumiko Furuno, Toshiro Motoya, Kazuaki Matsumoto, Tomohide Fukamizu, Naoko Fukunaga, Yoshihiro Shimodozono, Yasuo Takeda, Katsushi Yamada

Research output: Contribution to journalArticle

Abstract

High-dose methotrexate (HDMTX) chemotherapy has been established as a treatment for childhood acute lymphocytic leukemia and osteosarcoma. We retrospectively studied the relationship between HDMTX-related toxicity and concomitant drugs, namely, non-steroidal antiinflammatory drugs (NSAIDs) and sulfametoxazole, in HDMTX chemotherapy. A total of 516 patients on HDMTX who had undergone therapeutic drug monitoring were enrolled in this retrospective study. On these 516 cases, 196 were eligible for efficacy analysis, and MTX concentrations at 48 hours after MTX administration were determined. The 196 cases were divided into 3 groups as follows: the control group received no concomitant drugs which can affect MTX disposition; the NSAID group was administered oral and external-use NSAIDs within 24-hours before and after MTX administration; the sulfametoxazole group was administered sulfametoxazole within 24-hours before and after MTX dosing. The concentration levels of MTX at 48 hours after HDMTX were found to be significantly increased in the NSAID group (NSAIDs: 3.61 ± 8.83μM; control: 2.52 ± 23.7μM). In conclusion, this retrospective study indicates that concomitant NSAIDs significantly increase MTX serum concentrations, and should be avoided during treatment with HDMTX.

Original languageEnglish
Pages (from-to)11-14
Number of pages4
JournalJournal of Applied Therapeutic Research
Volume7
Issue number1
Publication statusPublished - 2009
Externally publishedYes

Fingerprint

Drug-Related Side Effects and Adverse Reactions
Methotrexate
Anti-Inflammatory Agents
Retrospective Studies
Drug Therapy
Pharmaceutical Preparations
Drug Monitoring
Osteosarcoma
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Control Groups
Therapeutics
Serum

Keywords

  • Drug interaction
  • High-dose methotrexate
  • NSAIDs
  • Sulfamethoxazole

ASJC Scopus subject areas

  • Pharmacology

Cite this

A retrospective study of the relationship between high-dose methotrexate chemotherapy-related toxicity and concomitant drugs : Non-steroidal anti-inflammatory drugs and sulfametoxazole. / Shibayama, Yoshihiko; Sata, Takuya; Furuno, Yumiko; Motoya, Toshiro; Matsumoto, Kazuaki; Fukamizu, Tomohide; Fukunaga, Naoko; Shimodozono, Yoshihiro; Takeda, Yasuo; Yamada, Katsushi.

In: Journal of Applied Therapeutic Research, Vol. 7, No. 1, 2009, p. 11-14.

Research output: Contribution to journalArticle

Shibayama, Yoshihiko ; Sata, Takuya ; Furuno, Yumiko ; Motoya, Toshiro ; Matsumoto, Kazuaki ; Fukamizu, Tomohide ; Fukunaga, Naoko ; Shimodozono, Yoshihiro ; Takeda, Yasuo ; Yamada, Katsushi. / A retrospective study of the relationship between high-dose methotrexate chemotherapy-related toxicity and concomitant drugs : Non-steroidal anti-inflammatory drugs and sulfametoxazole. In: Journal of Applied Therapeutic Research. 2009 ; Vol. 7, No. 1. pp. 11-14.
@article{60e103666089486e9a6b5bed50822b63,
title = "A retrospective study of the relationship between high-dose methotrexate chemotherapy-related toxicity and concomitant drugs: Non-steroidal anti-inflammatory drugs and sulfametoxazole",
abstract = "High-dose methotrexate (HDMTX) chemotherapy has been established as a treatment for childhood acute lymphocytic leukemia and osteosarcoma. We retrospectively studied the relationship between HDMTX-related toxicity and concomitant drugs, namely, non-steroidal antiinflammatory drugs (NSAIDs) and sulfametoxazole, in HDMTX chemotherapy. A total of 516 patients on HDMTX who had undergone therapeutic drug monitoring were enrolled in this retrospective study. On these 516 cases, 196 were eligible for efficacy analysis, and MTX concentrations at 48 hours after MTX administration were determined. The 196 cases were divided into 3 groups as follows: the control group received no concomitant drugs which can affect MTX disposition; the NSAID group was administered oral and external-use NSAIDs within 24-hours before and after MTX administration; the sulfametoxazole group was administered sulfametoxazole within 24-hours before and after MTX dosing. The concentration levels of MTX at 48 hours after HDMTX were found to be significantly increased in the NSAID group (NSAIDs: 3.61 ± 8.83μM; control: 2.52 ± 23.7μM). In conclusion, this retrospective study indicates that concomitant NSAIDs significantly increase MTX serum concentrations, and should be avoided during treatment with HDMTX.",
keywords = "Drug interaction, High-dose methotrexate, NSAIDs, Sulfamethoxazole",
author = "Yoshihiko Shibayama and Takuya Sata and Yumiko Furuno and Toshiro Motoya and Kazuaki Matsumoto and Tomohide Fukamizu and Naoko Fukunaga and Yoshihiro Shimodozono and Yasuo Takeda and Katsushi Yamada",
year = "2009",
language = "English",
volume = "7",
pages = "11--14",
journal = "Journal of Applied Therapeutic Research",
issn = "1029-2659",
publisher = "Euromed Communications",
number = "1",

}

TY - JOUR

T1 - A retrospective study of the relationship between high-dose methotrexate chemotherapy-related toxicity and concomitant drugs

T2 - Non-steroidal anti-inflammatory drugs and sulfametoxazole

AU - Shibayama, Yoshihiko

AU - Sata, Takuya

AU - Furuno, Yumiko

AU - Motoya, Toshiro

AU - Matsumoto, Kazuaki

AU - Fukamizu, Tomohide

AU - Fukunaga, Naoko

AU - Shimodozono, Yoshihiro

AU - Takeda, Yasuo

AU - Yamada, Katsushi

PY - 2009

Y1 - 2009

N2 - High-dose methotrexate (HDMTX) chemotherapy has been established as a treatment for childhood acute lymphocytic leukemia and osteosarcoma. We retrospectively studied the relationship between HDMTX-related toxicity and concomitant drugs, namely, non-steroidal antiinflammatory drugs (NSAIDs) and sulfametoxazole, in HDMTX chemotherapy. A total of 516 patients on HDMTX who had undergone therapeutic drug monitoring were enrolled in this retrospective study. On these 516 cases, 196 were eligible for efficacy analysis, and MTX concentrations at 48 hours after MTX administration were determined. The 196 cases were divided into 3 groups as follows: the control group received no concomitant drugs which can affect MTX disposition; the NSAID group was administered oral and external-use NSAIDs within 24-hours before and after MTX administration; the sulfametoxazole group was administered sulfametoxazole within 24-hours before and after MTX dosing. The concentration levels of MTX at 48 hours after HDMTX were found to be significantly increased in the NSAID group (NSAIDs: 3.61 ± 8.83μM; control: 2.52 ± 23.7μM). In conclusion, this retrospective study indicates that concomitant NSAIDs significantly increase MTX serum concentrations, and should be avoided during treatment with HDMTX.

AB - High-dose methotrexate (HDMTX) chemotherapy has been established as a treatment for childhood acute lymphocytic leukemia and osteosarcoma. We retrospectively studied the relationship between HDMTX-related toxicity and concomitant drugs, namely, non-steroidal antiinflammatory drugs (NSAIDs) and sulfametoxazole, in HDMTX chemotherapy. A total of 516 patients on HDMTX who had undergone therapeutic drug monitoring were enrolled in this retrospective study. On these 516 cases, 196 were eligible for efficacy analysis, and MTX concentrations at 48 hours after MTX administration were determined. The 196 cases were divided into 3 groups as follows: the control group received no concomitant drugs which can affect MTX disposition; the NSAID group was administered oral and external-use NSAIDs within 24-hours before and after MTX administration; the sulfametoxazole group was administered sulfametoxazole within 24-hours before and after MTX dosing. The concentration levels of MTX at 48 hours after HDMTX were found to be significantly increased in the NSAID group (NSAIDs: 3.61 ± 8.83μM; control: 2.52 ± 23.7μM). In conclusion, this retrospective study indicates that concomitant NSAIDs significantly increase MTX serum concentrations, and should be avoided during treatment with HDMTX.

KW - Drug interaction

KW - High-dose methotrexate

KW - NSAIDs

KW - Sulfamethoxazole

UR - http://www.scopus.com/inward/record.url?scp=77958074701&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77958074701&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:77958074701

VL - 7

SP - 11

EP - 14

JO - Journal of Applied Therapeutic Research

JF - Journal of Applied Therapeutic Research

SN - 1029-2659

IS - 1

ER -